Successful treatment of hidradenitis suppurativa requires a multidisciplinary team approach and multimodal therapy. (Plast. Reconstr. Surg. 147: 479e, 2021.)

Learning Objectives

After viewing this course, the participant should be able to:

1. Describe the pathogenesis of hidradenitis suppurativa. 
2. Discuss perioperative multimodal therapy of hidradenitis suppurativa, including medical optimization. 
3. Determine an appropriate surgical plan with excision and reconstruction based on hidradenitis suppurativa severity, size, and anatomical location.
   

Faculty

Plastic and Reconstruction Surgery®Editors: 
Editor-in-Chief: Rod J. Rohrich, MD
Co-Editor: James M. Stuzin, MD
Section Editors: Donald H. Lalonde, MD; John YS Kim, MD

Accreditation Information

This educational activity is intended for plastic surgery practitioners, residents, and other healthcare professionals interested in translating expanded knowledge into practice for the improvement of patient outcomes in plastic and reconstructive surgery.

Disclosures
Dr. Rohrich, MD is the Principal/Co-Principal Investigator of research grants awarded to the University of Texas Southwestern Medical Center, Dallas, from Medicis, Mentor, and Contura Pharmaceutical. All research funds are provided directly to UT Southwestern. Dr. Stuzin has no relevant financial relationships or affiliations to disclose. Dr. Lalonde is a consultant for ASSI Instruments. The authors have no disclosures. All ASPS staff members managing this activity have no relevant financial relationships or affiliations to disclose. All identified conflicts of interest have been resolved and the educational content thoroughly vetted by ASPS for fair balance, scientific objectivity, and appropriateness of patient care recommendations. The ASPS also requires faculty/authors to disclose when off-label/unapproved uses of a product are discussed in a CME activity or included in related materials.